Amarillo Biosciences (ABI) President Dr. Joseph M. Cummins to Address Japan Interferon Cytokine Research Conference in July 2004 to Discuss ABI's Development Plans for Oral Interferon Therapies in Animal and Human Health

Cargill Presented Paper Co-Authored By Dr. Cummins at 57th Reciprocal Meat Conference on June 23, 2004 Discussing Use of Oral Interferon as Alternative to Depopulation of Affected Animals AMARILLO, Texas, June 24 /PRNewswire-FirstCall/ -- Dr. Joseph M. Cummins, President and CEO of Amarillo Biosciences Inc. (OTC Bulletin Board: AMAR) (ABI) has accepted an invitation to speak at the Japan Interferon Cytokine Research meeting on July 31, 2004. The annual symposium is being held in Misawa City on Honshu Island where Dr. Cummins will review ABI's development plans for oral interferon in animal and human health. ABI's efforts to focus attention on the use of oral interferon to help combat foot-and-mouth disease (FMD) virus in livestock will also be discussed. Moreover, the mechanism of action of orally administered interferon will be reviewed. Separately, the Company announced that Dr. Albert Paszek of Cargill Inc., who shares ABI's concern about FMD, presented a paper June 23, 2004, at the 57th Reciprocal Meat Conference in Lexington, Kentucky as part of a presentation: FMD: Alternatives to Scorched Earth Policies." The paper was titled "Orally Administered Interferon to Prevent/Treat Foot-and-Mouth Disease" and was co-authored by Drs. Paszek and Cummins in addition to Drs. Steven Krakowka and David Hutcheson. Current planned response to the occurrence of FMD is to stop the movement of all livestock, slaughter and burial (or burning) of infected and exposed livestock and disinfection of affected/exposed farms. "If FMD virus is introduced by terrorists in multiple locations," said Dr. Cummins, "the government's attempt to eradicate FMD will require the slaughter and disposal of millions of animals. Nothing could please terrorists more than to watch the US Government kill millions of animals in response to their agroterrorism. After all, the FMD generally kills less than 1% of affected animals but the government's response kills 100%. What we need is a planned response that allows survival of our livestock. Dr. Paszek and I believe immune modulation with oral interferon and vaccination is a better way to respond to FMD." About Amarillo Biosciences, Inc. Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 32% of Amarillo Biosciences shares. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. Additional information is available on the ABI web site at http://www.amarbio.com . Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2003.